Literature DB >> 15906172

Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells.

Sinjan De1, Donald W Miller, Dennis H Robinson.   

Abstract

PURPOSE: To compare the effect of size of delivery systems on the cell-association and in vitro cytotoxicity of paclitaxel.
METHODS: Four sizes of PLGA-paclitaxel particles were prepared to study the effect of particle size on the cell-association of paclitaxel in 4T1 monolayer in the presence, and absence, of BCRP inhibitor, endocytic inhibitor, and P-glycoprotein (P-gp) inhibitor. Paclitaxel cell-association studies were repeated in Caco-2, Cor-L23/R, and bovine brain microvessel endothelial cells (BBMECs), as well as the association of etoposide in 4T1 cells. Cytotoxicity of paclitaxel to 4T1 cells delivered in nanospheres was compared to microspheres.
RESULTS: The concentration of paclitaxel and etoposide associated with 4T1 cells was 4.8 and 29 times greater, respectively, as the size increased from 310 to 2077 nm. Paclitaxel association consistently increased in Caco-2 and Cor-L23/R as the size of the delivery system increased. The endocytic inhibitor, 2-deoxyglucose, significantly decreased the cellular paclitaxel association when delivered by nanospheres but not microspheres. Consistent with the cell-association results, paclitaxel was thrice more cytotoxic to 4T1 cells when delivered in microspheres.
CONCLUSIONS: Cell-association of paclitaxel increased in 4T1, Caco-2, and Cor-L23/R as particle size increased. Paclitaxel delivered from 1-mum microspheres was thrice more cytotoxic to 4T1 cells compared to the drug delivered from nanospheres or solution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906172     DOI: 10.1007/s11095-005-2593-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  55 in total

Review 1.  Monotherapy of metastatic breast cancer: a review of newer agents.

Authors:  C L Vogel; J M Nabholtz
Journal:  Oncologist       Date:  1999

2.  Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.

Authors:  E Harper; W Dang; R G Lapidus; R I Garver
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

3.  Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy.

Authors:  Sinjan De; Dennis H Robinson
Journal:  AAPS PharmSciTech       Date:  2004-09-13       Impact factor: 3.246

4.  Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide.

Authors:  J C Shah; J R Chen; D Chow
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

5.  Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions.

Authors:  John K Jackson; Kevin C Skinner; Laurette Burgess; Tyler Sun; William L Hunter; Helen M Burt
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

6.  Description of a short-term Taxol-induced nociceptive neuropathy in rats.

Authors:  N Authier; J P Gillet; J Fialip; A Eschalier; F Coudore
Journal:  Brain Res       Date:  2000-12-29       Impact factor: 3.252

7.  The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent.

Authors:  M P Desai; V Labhasetwar; E Walter; R J Levy; G L Amidon
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

8.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.

Authors:  Attaya Suvannasankha; Hans Minderman; Kieran L O'Loughlin; Takeo Nakanishi; Laurie A Ford; William R Greco; Meir Wetzler; Douglas D Ross; Maria R Baer
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

9.  Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: possible function in insulin processing in the blood-brain barrier.

Authors:  D W Miller; B T Keller; R T Borchardt
Journal:  J Cell Physiol       Date:  1994-11       Impact factor: 6.384

10.  Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy.

Authors:  Yuping Zheng; Yasushi Ikuno; Masahito Ohj; Shunji Kusaka; Rui Jiang; Osman Cekiç; Miki Sawa; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2003 Mar-Apr       Impact factor: 2.447

View more
  4 in total

1.  Nanomedicine I: In vitro and in vivo evaluation of paclitaxel loaded poly-(ε-caprolactone), poly (DL-lactide-co-glycolide) and poly (DL-lactic acid) matrix nanoparticles in wistar rats.

Authors:  Sekar VasanthaKumar; Haja Nazeer Ahamed; Ranendra N Saha
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-27       Impact factor: 2.441

2.  Lymphatic Transport and Lymph Node Location of Microspheres Subcutaneously Injected in the Vicinity of Tumors in a Rabbit Model of Breast Cancer.

Authors:  Florentina Pascale; Laurent Bédouet; Afchine Fazel; Julien Namur; Saida Homayra Ghegediban; Isabelle Schwartz Cornil; Michel Wassef; Laurence Moine; Alexandre Laurent
Journal:  Pharm Res       Date:  2018-08-15       Impact factor: 4.200

3.  The behavior of lipid debris left on cell surfaces from microbubble based ultrasound molecular imaging.

Authors:  Stuart Ibsen; Guixin Shi; Carolyn Schutt; Linda Shi; Kyle-David Suico; Michael Benchimol; Viviana Serra; Dmitri Simberg; Michael Berns; Sadik Esener
Journal:  Ultrasonics       Date:  2014-07-01       Impact factor: 2.890

4.  Aptamer-labeled PLGA nanoparticles for targeting cancer cells.

Authors:  Athulya Aravind; Saino Hanna Varghese; Srivani Veeranarayanan; Anila Mathew; Yutaka Nagaoka; Seiki Iwai; Takahiro Fukuda; Takashi Hasumura; Yasuhiko Yoshida; Toru Maekawa; D Sakthi Kumar
Journal:  Cancer Nanotechnol       Date:  2012-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.